ImmuCell Other Long-Term Assets 2010-2024 | ICCC
ImmuCell other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
| ImmuCell Annual Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
| 2021 | $0 |
| 2020 | $0 |
| 2019 | $0 |
| 2018 | $0 |
| 2017 | $0 |
| 2016 | $0 |
| 2015 | $0 |
| 2014 | $0 |
| 2013 | $0 |
| 2012 | $0 |
| 2011 | $0 |
| 2010 | $0 |
| 2009 | $0 |
| ImmuCell Quarterly Other Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024-12-31 | $0 |
| 2024-09-30 | $0 |
| 2024-06-30 | $0 |
| 2024-03-31 | $0 |
| 2023-12-31 | $0 |
| 2023-09-30 | $0 |
| 2023-06-30 | $0 |
| 2023-03-31 | $0 |
| 2022-12-31 | $0 |
| 2022-09-30 | $0 |
| 2022-06-30 | $0 |
| 2022-03-31 | $0 |
| 2021-12-31 | $0 |
| 2021-09-30 | $0 |
| 2021-06-30 | $0 |
| 2021-03-31 | $0 |
| 2020-12-31 | $0 |
| 2020-09-30 | $1 |
| 2020-06-30 | $1 |
| 2020-03-31 | $1 |
| 2019-12-31 | $0 |
| 2019-09-30 | $0 |
| 2019-06-30 | $0 |
| 2019-03-31 | $0 |
| 2018-12-31 | $0 |
| 2018-09-30 | $0 |
| 2018-06-30 | $0 |
| 2018-03-31 | $0 |
| 2017-12-31 | $0 |
| 2017-09-30 | $0 |
| 2017-06-30 | $0 |
| 2017-03-31 | $0 |
| 2016-12-31 | $0 |
| 2016-09-30 | $0 |
| 2016-06-30 | |
| 2016-03-31 | $0 |
| 2015-12-31 | |
| 2015-09-30 | $0 |
| 2015-06-30 | $0 |
| 2015-03-31 | $0 |
| 2014-12-31 | $0 |
| 2014-09-30 | $0 |
| 2014-06-30 | $0 |
| 2014-03-31 | $0 |
| 2013-12-31 | $0 |
| 2013-09-30 | $0 |
| 2013-06-30 | $0 |
| 2013-03-31 | $0 |
| 2012-12-31 | $0 |
| 2012-09-30 | $0 |
| 2012-06-30 | $0 |
| 2012-03-31 | $0 |
| 2011-12-31 | $0 |
| 2011-09-30 | $0 |
| 2011-06-30 | $0 |
| 2011-03-31 | $0 |
| 2010-12-31 | $0 |
| 2010-09-30 | |
| 2010-06-30 | $0 |
| 2010-03-31 | $1 |
| 2009-12-31 | |
| 2009-09-30 | |
| 2009-06-30 | |
| 2009-03-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.048B | $0.026B |
| ImmuCell Corp. is a biotechnology company striving to build shareholder value by commercializing proprietary technologies and helping dairy and beef producers and their veterinarians manage disease and reproduction in their herds. The company is also conducting an open label, efficacy study of DiffGAM, a human application of its milk-derived passive antibodytechnology for use as an alternative to antibiotics in the treatment and/or prevention of Clostridium difficile-associated diarrhea. | |||